文献速递前列腺增生与排尿功能障碍

优化临床决策:一种可配置的良性前列腺增生治疗马尔可夫模型

Optimized Clinical Decision-making: A Configurable Markov Model for Benign Prostatic Hyperplasia Treatment.
PubMed 文献 · Urology · 2019-06-26

本研究设计了一种可配置的马尔可夫链模型,用于模拟良性前列腺增生不同健康状态及观察、药物治疗和4种微创激光手术间的转换,采用线性规划计算马尔可夫决策模型,主要结局为比较平均治疗成本的成本-效果曲线。模型为追求最佳患者结局(低国际前列腺症状评分)倾向于手术干预并增加治疗成本,在不同期望失用值断点间推荐按相对比例执行2种推荐治疗以实现最低成本与最优结局。

要点

  • 模型基于观察、药物治疗和4种微创激光手术模拟良性前列腺增生健康状态转换。
  • 为达到最佳患者结局(低国际前列腺症状评分),模型倾向于手术干预并增加治疗成本。
  • 在不同期望失用值断点间,模型推荐按相对比例执行2种推荐治疗以实现最低成本与最优结局。

核心结论

  • 该模型为医生、管理者和患者在考虑多种治疗及不同严重程度良性前列腺增生时优化成本-效果提供了工具,并可能配置用于其他疾病状态或临床实践。
  • 需要进一步研究验证该模型以用于现实应用。

研究设计与样本

  • 设计马尔可夫链模型模拟良性前列腺增生相关不同健康状态及基于特定干预(观察、药物治疗和4种微创激光手术)的状态间转换。
  • 转移概率、失用评分和各健康状态成本来源于文献、专家意见和医院管理数据。
  • 失用定义为效用补数(1-效用),效用代表特定状态相关的总体生活质量。
  • 采用线性规划计算马尔可夫决策模型。
  • 主要结局包括成本-效果曲线,在考虑所有建模干预的同时比较各允许失用水平下的平均治疗成本。

主要发现

  • 为达到最佳患者结局(低国际前列腺症状评分),模型倾向于手术干预并增加治疗成本。
  • 在不同期望失用值断点间,模型推荐按相对比例执行2种推荐治疗以实现最低成本与最优结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 模型受其理论基础限制,并依赖文献获取转移概率和生活质量评估。
  • 需要进一步研究验证该模型以用于现实应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present a configurable mathematical method to optimize long-term clinical decision-making for benign prostatic hyperplasia. METHODS: We designed a Markov chain model to simulate the different health states associated with benign prostatic hyperplasia and the transition between these states based on specific interventions: observation, pharmacotherapy, and 4 types of minimally invasive laser surgery. Transition probabilities, disutility scores, and costs for each health state were derived from the literature, expert opinion, and hospital administration data. Disutility was defined as the complement to one of the utility (1-utility), with utility representing the overall quality of life associated with a particular state. Linear programming was used to compute the Markov decision model. Primary outcomes include cost-effectiveness curves comparing the average treatment cost across permitted disutility levels while considering all modeled interventions. RESULTS: To achieve optimal patient outcomes (low International Prostate Symptoms Score), the model favored surgical interventions and increased costs of treatment. Between different desired disutility values (breakpoints), the model recommends performing 2 recommend treatments in relative proportions to achieve the lowest cost and optimal outcome. The model is limited by its theoretical basis and reliance on literature for transition probabilities and quality of life assessment. CONCLUSION: This model provides a tool for doctors, administrators, and patients to optimize cost-efficacy when considering multiple treatments and different severities of benign prostatic hyperplasia and may be configured to other disease states or clinical practices. Further studies are necessary to validate this model for real-life application.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Crivellaro S, Sofer L, Halgrimson WR, et al. Optimized Clinical Decision-making: A Configurable Markov Model for Benign Prostatic Hyperplasia Treatment. Urology. 2019. PMID: 31254572. doi:10.1016/j.urology.2019.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。